Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016:2016:1028945.
doi: 10.1155/2016/1028945. Epub 2015 Dec 29.

Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections

Feng-Fei Li  1 , Li-Yuan Fu  2 , Wen-Li Zhang  1 , Xiao-Fei Su  1 , Jin-Dan Wu  1 , Jin Sun  1 , Lei Ye  3 , Jian-Hua Ma  1
Affiliations
Randomized Controlled Trial

Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections

Feng-Fei Li et al. J Diabetes Res. 2016.

Abstract

To compare blood glucose fluctuations in type 2 diabetes mellitus (T2DM) patients were treated using three procedures: insulin intensive therapy which is continuous subcutaneous insulin infusion (CSII), MDI3 (three injections daily), and MDI4 (four injections daily). T2DM patients were hospitalized and were randomly assigned to CSII, aspart 30-based MDI3, and glargine based MDI4. Treatments were maintained for 2-3 weeks after the glycaemic target was reached. After completing the baseline assessment, 6-day continuous glucose monitoring (CGM) was performed before and after completion of insulin treatment. Treatment with CSII provided a greater improvement of blood glucose fluctuations than MDI (MDI3 or MDI4) therapy either in newly diagnosed or in long-standing T2DM patients. In long-standing diabetes patients, the MDI4 treatment group had significantly greater improvement of mean amplitude glycemic excursion (MAGE) than the MDI3 treatment group. However, in patients with newly diagnosed diabetes, there were no significant differences in the improvement of MAGE between MDI3 and MDI4 groups. Glargine based MDI4 therapy provided better glucose fluctuations than aspart 30-based MDI3 therapy, especially in long-standing T2DM patients, if CSII therapy was not available.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The effect of transient insulin intensive therapy on β-cell function and insulin resistance.
See this image and copyright information in PMC

References

    1. Riddle M., Umpierrez G., DiGenio A., et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34:2508–2514. - PMC - PubMed
    1. Ilkova H., Glaser B., Tunçkale A., Bagriaçik N., Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care. 1997;20(9):1353–1356. doi: 10.2337/diacare.20.9.1353. - DOI - PubMed
    1. Li Y., Xu W., Liao Z., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care. 2004;27(11):2597–2602. doi: 10.2337/diacare.27.11.2597. - DOI - PubMed
    1. Retnakaran R., Drucker D. J. Intensive insulin therapy in newly diagnosed type 2 diabetes. The Lancet. 2008;371(9626):1725–1726. doi: 10.1016/S0140-6736(08)60736-9. - DOI - PubMed
    1. Ryan E. A., Imes S., Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27(5):1028–1032. doi: 10.2337/diacare.27.5.1028. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources